What is Enfortumab?

Enfortumab is a cancer-specific drug used to treat advanced or metastatic urothelial carcinoma (urothelial carcinoma). Urothelial carcinoma is a rare but dangerous type of cancer that commonly occurs in the epithelial tissue of the bladder, urethra, and renal pelvis.

Ennosumab belongs to a class of drugs called immunotoxin conjugates (immunotoxin conjugates ). It works by binding to a receptor on the surface of tumor cells called Nectin-4. This receptor is overexpressed in many urothelial cancers, making it a target for drugs. Once ennosumab binds to Nectin-4, the drug enters the inside of the cancer cells and releases the toxin, causing the cancer cells to die.

Clinical studies of ennosumab have demonstrated significant efficacy in the treatment of advanced urothelial cancer. Many patients show tumor shrinkage or stabilization after treatment with ennosumab, thereby extending their survival and quality of life. However, like all medications, ennosumab may cause some side effects, including fatigue, nausea, vomiting, diarrhea, and immune system-related reactions.

Ennosumab is usually administered by intravenous injection and is administered by a medical professional in a medical setting. During treatment, doctors will closely monitor the patient's condition and drug tolerance and make adjustments as needed.

Ennosumab is not currently available in China, so patients cannot purchase it domestically and need to purchase ennosumab through overseas channels. There are only enromonumab original drugs in foreign countries, and there are no generic drugs. They are mainly Japanese original drugs, and the price is more than 10,000 yuan.